Pelvic exenteration for gynaecological cancer: a 10-year cohort analysis from a tertiary centre in the UK

Background: Pelvic exenteration provides a valuable curative treatment option for recurrent or persistent gynaecological malignancies. This case series describes the surgical outcomes and complications of pelvic exenteration surgery in patients with recurrent or persistent gynaecological cancer over a 10-year period at a tertiary university teaching hospital. Methods: Data were collected from the electronic medical record system (Epic Systems) at Cambridge University Hospital between October 2014 and 15 September 2023. The study was conducted as part of a service evaluation. Data were collected and analyzed for patient characteristics, pre-exenteration primary treatment profiles, perioperative complications, survival profiles and follow-up duration. Results: Out of 136 pelvic exenterations performed during the study period, 16 were undertaken for gynaecological cancer. The median age at the time of exenteration was 59.5 years (interquartile range (IQR), 55–66 years). Cervical cancer was the most common primary tumor (5/16, 31.3%). Three patients had vulvar cancer (18.8%), two had vaginal cancer (12.5%), and three had uterine cancer (18.8%). We observed severe (III/IV) complications in 3 out of 16 patients within 30 days of postoperative period. There were no postoperative deaths within 30 days. The median follow-up period was 37.1 months (95% confidence interval (CI): 26.4–47.7). No mortality occurred within 90 days, and the 5-year survival rate was 43.8% (7/16). Conclusions: With a carefully selected patient group, pelvic exenteration represents a safe and curative approach for recurrent or persistent gynaecological cancers.

Gynaecological cancer; Pelvic exenteration; Surgical outcome

[1] Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948; 1: 177–183.

[2] da Silva IA, Carneiro ICDRS, de Santana ME, Ferreira IP. Postoperative complications associated with pelvic exenteration in women with gynecological cancer: an integrative review. Cogitare Enfermagem. 2023; 28: e82317.

[3] Tortorella L, Casarin J, Mara KC, Weaver AL, Multinu F, Glaser GE, et al. Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies. Gynecologic Oncology. 2019; 152: 151–156.

[4] Tortorella L, Marco C, Loverro M, Carmine C, Persichetti E, Bizzarri N, et al. Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience. Journal of Gynecologic Oncology. 2024; 35: e4.

[5] Lewandowska A, Szubert S, Koper K, Koper A, Cwynar G, Wicherek L. Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer. World Journal of Surgical Oncology. 2020; 18: 234.

[6] Stanca M, Căpîlna DM, Căpîlna ME. Long-term survival, prognostic factors, and quality of life of patients undergoing pelvic exenteration for cervical cancer. Cancers. 2022; 14: 2346.

[7] PelvExCollaborative. A review of functional and surgical outcomes of gynaecological reconstruction in the context of pelvic exenteration. Surgical Oncology. 2024; 52: 101996.

[8] PelvExCollaborative. Pelvic exenteration for advanced nonrectal pelvic malignancy. Annals of Surgery. 2019; 270: 899–905.

[9] Matsuo K, Mandelbaum RS, Adams CL, Roman LD, Wright JD. Performance and outcome of pelvic exenteration for gynecologic malignancies: a population-based study. Gynecologic Oncology. 2019; 153: 368–375.

[10] Li C, Li Z, Zhang J, Zhang X, Siesto G, Li S, et al. Retrospective study of combined pelvic exenteration in the treatment of primary and recurrent pelvic malignant tumors. Journal of Gastrointestinal Oncology. 2024; 15: 299–311.

[11] Peacock O, Waters PS, Kong JC, Warrier SK, Wakeman C, Eglinton T, et al. Complications after extended radical resections for locally advanced and recurrent pelvic malignancies: a 25-year experience. Annals of Surgical Oncology. 2020; 27: 409–414.

[12] Karkia R, Tailor A, Ellis P, Madhuri T, Scala A, Read J, et al. Minimally invasive pelvic exenteration for gynaecological malignancy: a single-centre case series and review of the literature. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2022; 274: 56–61.

[13] Moolenaar LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, van Driel WJ, van Lonkhuijzen LRCW, et al. Clinical outcomes of pelvic exenteration for gynecologic malignancies. Gynecologic Oncology. 2023; 171: 114–120.

[14] Glane LT, Hegele A, Wagner U, Boekhoff J. Gynecologic oncology: pelvic exenteration for advanced or recurring cervical cancer—a single center analysis. Cancer Diagnosis & Prognosis. 2022; 2: 308–315.

[15] Lyell NJ, Kitano M, Smith B, Gleisner AL, Backes FJ, Cheng G, et al. The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: a multi-disciplinary, multi-institutional cohort study. The American Journal of Surgery. 2019; 218: 275–280.

[16] Pathiraja P, Sandhu H, Instone M, Haldar K, Kehoe S. Should pelvic exenteration for symptomatic relief in gynaecology malignancies be offered? Archives of Obstetrics and Gynaecology. 2014; 289: 657–662.

[17] Fleisch MC, Pantke P, Beckmann MW, Schnuerch HG, Ackermann R, Grimm MO, et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. Journal of Surgical Oncology. 2007; 95: 476–484.

[18] Straubhar AM, Chi AJ, Zhou QC, Iasonos A, Filippova OT, Leitao MM III, et al. Pelvic exenteration for recurrent or persistent gynecologic malignancies: clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecologic Oncology. 2021; 163: 294–298.

[19] Kuzma T, Glaze S, Duan Q, Duttchen K. Preoperative hypoalbuminemia is associated with increased mortality in patients undergoing surgery for gynaecologic malignancy—a retrospective cohort study. Journal of Obstetrics and Gynaecology Canada. 2023; 45: 395–401.

[20] Esmailzadeh A, Fakhari MS, Saedi N, Shokouhi N, Almasi-Hashiani A. A systematic review and meta-analysis on mortality rate following total pelvic exenteration in cancer patients. BMC Cancer. 2024; 24: 593.

[21] Pleth Nielsen CK, Sørensen MM, Christensen HK, Funder JA. Complications and survival after total pelvic exenteration. European Journal of Surgical Oncology. 2022; 48: 1362–1367.

[22] Yu JH, Tong CJ, Huang QD, Ye YL, Chen G, Li H, et al. Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study. BMC Cancer. 2024; 24: 88.